Daniel O'Day, Gilead CEO (Kevin Dietsch/UPI/Bloomberg via Getty Images)

Play-by-play of Gilead­'s $21B Im­munomedics buy­out de­tails a fren­zied push — and mints a new biotech bil­lion­aire

Im­munomedics had not re­al­ly been look­ing for a buy­out when the year be­gan. Ex­cit­ed by its BLA for Trodelvy, sub­mit­ted to the FDA in late 2019, ex­ec­u­tive chair­man Be­hzad Ag­haz­adeh start­ed off look­ing for po­ten­tial li­cens­ing deals and ze­roed in on four po­ten­tial part­ners, in­clud­ing Gilead, fol­low­ing Jan­u­ary’s JP Mor­gan Health­care Con­fer­ence in San Fran­cis­co. Such talks ad­vanced through­out the year, with dis­cus­sions ad­vanc­ing to the sec­ond round in mid-Au­gust.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.